Purging of autologous bone marrow for transplantation: the protection and selection of the hematopoietic progenitor cell.


Journal Article (Review)

Autologous bone marrow transplantation (ABMT) is the treatment of choice for selected patients with acute myelogenous leukemia, non-Hodgkin's lymphoma, and poor prognosis breast cancer. A possible limitation of this approach is that clonogenic tumor cells could be collected and infused back into the patient along with the normal bone marrow. The major emphasis in our laboratory has been the development of marrow purging regimens for breast cancer patients. This paper describes two investigative approaches hematopoietic progenitor cell protection and selection. We describe how the use of G-CSF in the patients who receive positively selected marrow shortens the rate of engraftment.

Full Text

Duke Authors

Cited Authors

  • Shpall, EJ; Stemmer, SM; Johnston, CF; Hami, L; Bearman, SI; Berenson, R; Jones, RB

Published Date

  • 1992

Published In

Volume / Issue

  • 1 / 1

Start / End Page

  • 45 - 54

PubMed ID

  • 1365017

Pubmed Central ID

  • 1365017

International Standard Serial Number (ISSN)

  • 1061-6128

Digital Object Identifier (DOI)

  • 10.1089/scd.1.1992.1.45


  • eng

Conference Location

  • United States